KR920003971A - 점안액 조성물 - Google Patents

점안액 조성물 Download PDF

Info

Publication number
KR920003971A
KR920003971A KR1019910013973A KR910013973A KR920003971A KR 920003971 A KR920003971 A KR 920003971A KR 1019910013973 A KR1019910013973 A KR 1019910013973A KR 910013973 A KR910013973 A KR 910013973A KR 920003971 A KR920003971 A KR 920003971A
Authority
KR
South Korea
Prior art keywords
composition
concentration
soluble polymer
polymer compound
cyclotextrin
Prior art date
Application number
KR1019910013973A
Other languages
English (en)
Inventor
가즈미찌 우시오
요시후미 이께지리
Original Assignee
요시다 쇼우지
센쥬세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요시다 쇼우지, 센쥬세이야꾸 가부시끼가이샤 filed Critical 요시다 쇼우지
Publication of KR920003971A publication Critical patent/KR920003971A/ko

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

내용 없음

Description

점안액 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 주 유효 성분으로서 3,4-디히드로-2,8-디이소프로필-3-티옥소-2H-1,4-벤족사진-4-아세트산 또는 그의 약학적 허용 가능한 염 및 시클로텍스트린을 함유하는 점안액 조성물.
  2. 제1항에 있어서, 시클로텍스트린이 β-시클로텍스트린인 조성물.
  3. 제1항에 있어서, 주 유효 성분의 농도가 0.01 내지 1W/V%인 조성물.
  4. 제1항에 있어서, 시클로텍스트린의 농도가 0.005 내지 1W/V%인 조성물.
  5. 제1항에 있어서, 조성물이 수용성 중합체 화합물을 더 함유하는 조성물.
  6. 제5항에 있어서, 수용성 중합체 화합물이 분자량 5,000 내지 5,000,000를 갖는 조성물.
  7. 제5항에 있어서, 수용성 중합체 화합물의 농도가 0.2 내지 20W/V%인 조성물.
  8. 제5항에 있어서, 수용성 중합체 화합물이 폴리비닐 피롤리돈, 폴리비닐 알코올, 히드록시프로필메틸셀룰로오스, 카르복실프로필 셀룰로오스, 히드록시에틸 셀룰로오스, 히드록시프로필 셀룰로오스 및 소듐 폴리아크릴레이트로 구성된 군에서 선택된 조성물.
  9. 제7항에 있어서, 수용성 중합체 화합물이 분자량 25,000 내지 120,000를 갖는 폴리비닐 피롤리돈인 조성물.
  10. 제5항에 있어서, 조성물이 킬레이트제를 더 함유하는 조성물.
  11. 제10항에 있어서, 킬레이트제의 농도가 0.01 내지 1W/V%인 조성물.
  12. 제10항에 있어서, 킬레이트제가 디소듐 에데테이트, 소듐 시트레이트 및 축합 소듐 포스페이트로 구성된 군에서 선택된 조성물.
  13. 제10항에 있어서, 조성물이 붕산을 더 함유하는 조성물.
  14. 제5항에 있어서, 붕산의 농도가 0.2 내지 4W/V%인 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910013973A 1990-08-13 1991-08-13 점안액 조성물 KR920003971A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP90-214827 1990-08-13
JP21482790 1990-08-13
JP16285491 1991-07-03
JP91-162854 1991-07-03

Publications (1)

Publication Number Publication Date
KR920003971A true KR920003971A (ko) 1992-03-27

Family

ID=26488494

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910013973A KR920003971A (ko) 1990-08-13 1991-08-13 점안액 조성물

Country Status (16)

Country Link
US (1) US5663170A (ko)
EP (1) EP0472327B1 (ko)
JP (1) JP2769253B2 (ko)
KR (1) KR920003971A (ko)
AT (1) ATE121295T1 (ko)
AU (1) AU633754B2 (ko)
CA (1) CA2048942A1 (ko)
DE (1) DE69109021T2 (ko)
DK (1) DK0472327T3 (ko)
ES (1) ES2071227T3 (ko)
FI (1) FI97777C (ko)
HU (1) HU207950B (ko)
NO (1) NO177845C (ko)
PT (1) PT98643B (ko)
RU (1) RU2068260C1 (ko)
TW (1) TW200402B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0589020A4 (en) * 1992-03-18 1994-07-06 Coopervision Pharma Verapamil hcl formulation and other ophthalmic solutions with buffer system for ocular administration
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
WO1994010976A1 (en) * 1992-11-16 1994-05-26 Ciba Vision Ag, Hettlingen Polyvinyl alcohol/borate ophthalmic drug delivery system
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
SE501482C2 (sv) * 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
WO1995003784A1 (en) * 1993-07-28 1995-02-09 Insite Vision Incorporated Suspensions for delivery of medicament
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
US5977180A (en) * 1994-07-11 1999-11-02 Pate; David W. Anandamide analog compositions and method of treating intraocular hypertension using same
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
HUT77445A (hu) * 1995-01-20 1998-04-28 Wakamoto Pharmaceutical Co. Ltd. Gyulladásgátló szemcsepp
EP0807434B1 (en) * 1995-01-20 2002-04-10 Wakamoto Pharmaceutical Co., Ltd. Anti-inflammatory eyedrops
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
JP2001125052A (ja) * 1999-10-25 2001-05-11 Lion Corp コンタクトレンズ装着液
WO2001097852A1 (fr) * 2000-06-19 2001-12-27 Santen Pharmaceutical Co., Ltd. Agents aseptiques
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
WO2006137433A1 (ja) * 2005-06-21 2006-12-28 Wakamoto Pharmaceutical Co., Ltd. レボカバスチンを可溶化させた水性薬剤
US20100069335A1 (en) * 2005-07-15 2010-03-18 Rajiv Bhushan Prevention and Treatment of Ophthalmic Complications of Diabetes
MX353874B (es) 2012-03-26 2018-02-01 Santen Pharmaceutical Co Ltd Gotas para los ojos que contienen diquafosol.
AU2019261437A1 (en) * 2018-04-27 2020-12-17 Allergan, Inc. Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity
CN114746079A (zh) * 2019-11-21 2022-07-12 三进制药株式会社 用于预防或治疗眼部疾病的滴眼剂组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602641B2 (en) * 1986-04-17 1990-10-18 Senju Pharmaceutical Co., Ltd. Thiolactam-N-acetic acid derivatives, their production and use

Also Published As

Publication number Publication date
FI97777B (fi) 1996-11-15
DE69109021T2 (de) 1995-09-21
DK0472327T3 (da) 1995-05-08
HU912692D0 (en) 1992-01-28
AU633754B2 (en) 1993-02-04
FI913811A (fi) 1992-02-14
EP0472327B1 (en) 1995-04-19
HU207950B (en) 1993-07-28
US5663170A (en) 1997-09-02
PT98643B (pt) 1999-01-29
JP2769253B2 (ja) 1998-06-25
NO177845C (no) 1995-12-06
CA2048942A1 (en) 1992-02-14
FI913811A0 (fi) 1991-08-12
DE69109021D1 (de) 1995-05-24
PT98643A (pt) 1992-07-31
RU2068260C1 (ru) 1996-10-27
TW200402B (ko) 1993-02-21
ES2071227T3 (es) 1995-06-16
JPH05213757A (ja) 1993-08-24
NO913136L (no) 1992-02-14
NO913136D0 (no) 1991-08-12
FI97777C (fi) 1997-02-25
HUT61196A (en) 1992-12-28
ATE121295T1 (de) 1995-05-15
AU8170891A (en) 1992-02-20
NO177845B (no) 1995-08-28
EP0472327A1 (en) 1992-02-26

Similar Documents

Publication Publication Date Title
KR920003971A (ko) 점안액 조성물
DK0788350T3 (da) Dannelse af små partikler
CA2295061C (en) Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin
ATE362755T1 (de) Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen
BR9507640A (pt) Processo para estabilizar derivados de duocarmicida e composição farmacêutica
ATE61050T1 (de) Pyridazinamine wirksam gegen viren.
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
ATE252369T1 (de) Konservierungssysteme fur cyclodextrine enthaltende arzneimittel
FI940696A0 (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
CA2057291A1 (en) A stable pharmaceutical composition of human calcitonin
FI913433A0 (fi) Foerfarande foer foerhindrande eller begraensande av skada vid aoterstroemning av blod genom ett organ eller en vaevnad.
KR970061246A (ko) 테스토스테론을 증가시키기 위한 약학 조성물
KR960705563A (ko) 펜벤다졸 제형(Fenbendazole formulations)
CA2051621A1 (en) Oil-in-water type emulsified composition comprising non-steroidal antiphlogistic and analgesic drug
NO954952D0 (no) Fremgangsmåte for fremstilling av en oral fast-stoff doseringsform som inneholder diklofenac
NO980058L (no) Opthalmiske preparater
AR007052A1 (es) Un derivado de carbohidrato, su uso y una composicion farmaceutica que lo comprende
NO973401L (no) Kortikosteroidinneholdende sammensetninger og fremstilling derav
JPS5989617A (ja) 点眼液
KR900013959A (ko) γ-카르블린 또는 그들의 제약학적으로 허용 가능한 산부가염 및/또는 수화물, 및 그들로 구성되는 제약학적 조성물
SE9001592D0 (sv) A therapeutical composition
KR920002594A (ko) 5-이소티아졸아민 유도체
JPS6217973B2 (ko)
KR860002498A (ko) 1,4-디하이드로피리딘 유도체의 약학조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application